

ATTORNEY DOCKET No.	SERIAL NO.
6102-000048/US/NP	10/593,964
APPLICANT	
Scheller, D.	
FILING DATE	GROUP
September 22, 2006	1614

Sheet 1 of 2
--------------

U.S. PATENT DOCUMENTS							
Ref. Desig.			Publication Date	Name	Class/ Subclass	Filing Date	
		2004/0116537	Jun 17, 2004	Li et al.	514/663	Nov 17, 2003	
		2005/0197385	Sep 08, 2005	Scheller et al.	514/438	Feb 17, 2005	

FOREI	FOREIGN PATENT DOCUMENTS							
Ref. Examiner's Initials		Document Number	Publication Date	Country	Class/ Subclass	Transla Yes	tion No	
		CA 2 546 797	Jul 14, 2005	CA	A61K			
		WO 96/31210	Oct 10, 1996	PCT	A61K			
		WO 99/49852	Oct 07, 1999	PCT	A61K	х		
		WO 02/15903	Feb 28, 2002	PCT	A61K	X		
		WO 02/38646	May 16, 2002	PCT	C08G	Х		
		WO 02/89777	Nov 14, 2002	PCT	A61K			
		WO 02/89778	Nov 14, 2002	PCT	A61K			
		WO 04/012721	Feb 12, 2004	PCT	A61K	Х		
		WO 04/012730	Feb 12, 2004	PCT	A61K			
	-	WO 04/058247	Jul 15, 2004	PCT	A61K	×		
		WO 05/070428	Aug 04, 2005	PCT	A61K			

OTHER DOCUMENTS (including Author, Title, Date, Pages, etc.)		
Ref. Desig.	Examiner's Initials	
		Dawson (2002) Nature Neuroscience Supplement, Vol 5, 1058-1061
		Den Daas (1990) Naunyn-Schmiedeberg's Archives of Pharmacology 341, 186-191
		Den Daas (1990) Naunyn-Schmiedeberg's 342, 655-659
		Den Daas (1991) J. Pharm. Pharmacology 43, 11-16
		Eberhardt (2003) Toxicology Letter 139(2), 135-151
		Fahn et al. (1987) Recent Developments in Parkinson's Disease Vol 2, pp 153-163, 293-294

Examiner: /Sahar Javanmard/ Date Considered: 08/03/2009	Examiner:	/Sanai Javaninaiu/	Date Considered:	08/03/2009
---	-----------	--------------------	------------------	------------

## FORM HDP-1449 (Based on Form PTO-1449)

## PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2 of 2

ATTORNEY DOCKET NO.	SERIAL NO.	
6102-000048/US/NP	10/593,964	
APPLICANT		
Scheller, D.		
FILING DATE	GROUP	
September 22, 2006	1614	

OTHER	OTHER DOCUMENTS (including Author, Title, Date, Pages, etc.)				
Ref. Desig.	Examiner's Initials				
		Gerlach (2003) Neurotox. Res. 5(1), 43-51			
		Hirsch (2003) Ann NY Academy Science 991, 214-228			
		Hobson (2003) Can. J. Neurol. Sci. 30(Suppl 1) S2-S9			
		Lev (2003) Prog. Neuropsychopharm. Biol. Psychiatry 27(2), 245			
		Mark (2001) Neurol. Clin. 19(3), 607-627			
		Metman (2001) Clinical Neuropharmcology 24(3), 163-169			
		Michel et al. (2002) Rev. Neurol. (Paris) 158 Spec No. 1, pp 7S24-7S32			
		Mucke (2003) IDrugs 6(9), 894-899			
		Neophytides et al. (1982) J. Neurology Neurosurgery Psychiatry 45, 261-263			
		Newman-Tancredit et al. (2002) J. Pharm. And Experimental Ther. 303(2), 805-814			
		Parkinson Study Group (2003) Arch. Neurol. 60(12), 1721-1728			
		Pascual (1992) Annals of Neurology 32(5), 703-707			
		Pierot (1988) J. Neurological Sciences 86, 291-306			
		Tuite (2003) Expert Opin. Investig. Drugs 12(8), 1335-1352			
		Vila (2003) Nat. Rev. Neurosci 4(5), 365			
		Wenning et al. (2004) Lancet Neurology 3, 93-103			

Examiner:	/Sahar Javanmard/	Date Considered:	08/03/2009	

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.